{
    "clinical_study": {
        "@rank": "119458", 
        "arm_group": [
            {
                "arm_group_label": "Ragweed-SPIRE 1", 
                "arm_group_type": "Experimental", 
                "description": "Ragweed-SPIRE regimen 1 given 2 weeks apart"
            }, 
            {
                "arm_group_label": "Ragweed-SPIRE 2", 
                "arm_group_type": "Experimental", 
                "description": "Ragweed-SPIRE regimen 2 given 2 weeks apart"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given 2 weeks apart"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to\n      subjects suffering from both ragweed allergy and asthma."
        }, 
        "brief_title": "Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Seasonal Allergic Rhinitis", 
            "Asthma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Asthma", 
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 18-65 years.\n\n          -  Asthma treated by inhaled SABA or inhaled SABA plus low-medium dose ICS in 6 weeks\n             prior to randomisation.\n\n          -  A reliable history consistent with moderate to severe rhinoconjunctivitis on exposure\n             to ragweed for at least the previous two ragweed seasons.\n\n          -  Positive skin prick test to ragweed\n\n          -  Ragweed-specific Immunoglobulin E (IgE) \u2265 0.35 kU/L.\n\n        Exclusion Criteria:\n\n          -  History of life-threatening asthma.\n\n          -  Uncontrolled asthma according to GINA\n\n          -  FEV1 of < 70 % of predicted, regardless of the cause.\n\n          -  Administration of adrenaline (epinephrine) is contraindicated (e.g. subjects with\n             acute or chronic symptomatic coronary heart disease or severe hypertension).\n\n          -  History of severe drug allergy or anaphylactic reaction to food.\n\n          -  A history of any significant disease or disorder (e.g. immune system, pulmonary,\n             cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal,\n             endocrine, metabolic, malignant, psychiatric, major physical impairment, history of\n             alcohol or drug abuse)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061670", 
            "org_study_id": "TR007"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ragweed-SPIRE 1", 
                    "Ragweed-SPIRE 2"
                ], 
                "description": "Intradermal injection", 
                "intervention_name": "Ragweed-SPIRE", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ragweed", 
            "Allergy", 
            "rhinoconjunctivitis", 
            "rhinitis", 
            "asthma"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kanata", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K2L 3C8"
                    }, 
                    "name": "Kanata Allergy Services"
                }, 
                "investigator": {
                    "last_name": "Charles W Frankish, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kingston", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K7L 2V7"
                    }, 
                    "name": "Kingston General Hospital"
                }, 
                "investigator": {
                    "last_name": "Anne Ellis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mississauga", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L5A 3V"
                    }, 
                    "name": "Cheema Research Inc"
                }, 
                "investigator": {
                    "last_name": "Amarjit Cheema, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1Y 4G2"
                    }, 
                    "name": "Ottawa Allergy Research Corp"
                }, 
                "investigator": {
                    "last_name": "William Yang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L4W 1A4"
                    }, 
                    "name": "Inflamax Research"
                }, 
                "investigator": {
                    "last_name": "Janice Faulknor, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis", 
        "overall_contact": {
            "email": "deborah.bates@pharm-olam.com", 
            "last_name": "Deborah Bates"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Throughout subjects participation in the study, approximately 22 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061670"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects with asthma exacerbations as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Throughout subjects participation in the study, approximately 22 weeks"
            }, 
            {
                "measure": "Evaluation of change in lung function as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Throughout subjects participation in the study, approximately 22 weeks"
            }
        ], 
        "source": "Circassia Limited", 
        "sponsors": {
            "collaborator": {
                "agency": "Adiga Life Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Circassia Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}